Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
February 23, 2026: New Weight Loss Drug Fails to Outperform Zepbound in Clinical Trial Zepbound was not outperformed in a clinical trial of a competitors new GLP-1 weight loss drug formulation
Background On GLP-1 Medication Demand And Supply Shortages The demand for GLP-1 medications has skyrocketed, driven by their effectiveness in managing type 2 diabetes and promoting weight loss
Due to tirzepatide's long half-life (approximately five days) and delayed peak concentration (8-72 hours after injection), symptoms typically reflect steady-state effects rather than immediate post-injection peaks
Never throw used needles into the regular trash
It works by binding to the fat you eat and stopping it from being absorbed by your body
When these treatments are combined, it is possible that a person may experience more pronounced side effects, although these cases are rare
